A New Paradigm for KIM-PTP Drug Discovery: Identification of Allosteric Sites with Potential for Selective Inhibition Using Virtual Screening and LEI Analysis by Adams, James et al.
 International Journal of 
Molecular Sciences
Article
A New Paradigm for KIM-PTP Drug Discovery: Identification
of Allosteric Sites with Potential for Selective Inhibition Using
Virtual Screening and LEI Analysis
James Adams 1, Benjamin P. Thornton 1 and Lydia Tabernero 1,2,3,*


Citation: Adams, J.; Thornton, B.P.;
Tabernero, L. A New Paradigm for
KIM-PTP Drug Discovery:
Identification of Allosteric Sites with
Potential for Selective Inhibition
Using Virtual Screening and LEI
Analysis. Int. J. Mol. Sci. 2021, 22,
12206. https://doi.org/10.3390/
ijms222212206
Academic Editor: Gerard Pujadas
Received: 12 October 2021
Accepted: 6 November 2021
Published: 11 November 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 School of Biological Sciences, Faculty of Biology Medicine and Health, Manchester Academic Health Science
Centre, University of Manchester, Manchester M13 9PT, UK; jadams_91@hotmail.co.uk (J.A.);
benjamin.thornton-3@postgrad.manchester.ac.uk (B.P.T.)
2 Lydia Becker Institute for Immunology and Inflammation, University of Manchester,
Manchester M13 9PT, UK
3 Antimicrobial Resistance Network, University of Manchester, Manchester M13 9PT, UK
* Correspondence: Lydia.Tabernero@manchester.ac.uk; Tel.: +44-(0)-161-275-7794
Abstract: The kinase interaction motif protein tyrosine phosphatases (KIM-PTPs), HePTP, PTPSL and
STEP, are involved in the negative regulation of mitogen-activated protein kinase (MAPK) signalling
pathways and are important therapeutic targets for a number of diseases. We have used VSpipe, a
virtual screening pipeline, to identify a ligand cluster distribution that is unique to this subfamily
of PTPs. Several clusters map onto KIM-PTP specific sequence motifs in contrast to the cluster
distribution obtained for PTP1B, a classic PTP that mapped to general PTP motifs. Importantly, the
ligand clusters coincide with previously reported functional and substrate binding sites in KIM-PTPs.
Assessment of the KIM-PTP specific clusters, using ligand efficiency index (LEI) plots generated
by the VSpipe, ascertained that the binders in these clusters reside in a more drug-like chemical–
biological space than those at the active site. LEI analysis showed differences between clusters across
all KIM-PTPs, highlighting a distinct and specific profile for each phosphatase. The most druggable
cluster sites are unexplored allosteric functional sites unique to each target. Exploiting these sites
may facilitate the delivery of inhibitors with improved drug-like properties, with selectivity amongst
the KIM-PTPs and over other classical PTPs.
Keywords: protein phosphatases (PPases); phosphatase inhibitors; hematopoietic protein tyrosine
phosphatase (HePTP); striatum-enriched protein tyrosine phosphatase (STEP); protein tyrosine
phosphatase SL (PTP-SL); kinase interaction motif protein tyrosine phosphatases (KIM-PTPs); com-
putational screening; virtual screening (VS); VSpipe; ligand efficiency indices (LEIs); drug discovery
1. Introduction
Protein tyrosine phosphatases (PTPs) are fundamental regulators of numerous biolog-
ical pathways and important therapeutic targets for multiple diseases [1–6]. A subfamily
of PTPs are the kinase interaction motif protein tyrosine phosphatases (KIM-PTPs): HePTP,
PTPSL and STEP. KIM-PTPs are involved in the negative regulation of mitogen-activated
protein kinase (MAPK) signalling pathways [7–10], and represent important therapeutic
targets for cancer [11,12], or neurodegenerative diseases [13,14].
Given their therapeutic importance, several investigations into their inhibition have
also been undertaken [15–18], together with their activation [19]. However, inhibition of
PTPs has historically been problematic because of the highly conserved active site and
its polar nature [20]. Focus has now turned to target regulatory mechanisms, including
allosteric regulation, protein oligomerisation and redox modulation [21–23].
Particularly, targeting sites distal to the active site offers new opportunities to develop
compounds with increased selectivity and drug-like properties [23]. Examples include the
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targeting of different conformational states of RPTPG [24], allosteric sites of PTP1B [25,26]
and SHP2 [27], or the trimer interface of PRL [28].
The development of allosteric inhibitors raises a new challenge in the identification
of the allosteric site for subsequent targeting often requiring different biochemical and
structural methods, which are time consuming. Computational approaches to find ligand
binding sites are widely used because they are fast, cheaper and a good complement
to experimental methods. We recently reported the use of the virtual screening tool,
VSpipe [29], to effectively identify functional ligand binding sites on PTP1B, including an
allosteric inhibitor site, and on fungal phosphatases [30]. The ability of VSpipe to perform
rapid blind docking of compound libraries, together with the assessment of the ligand
efficiency indices (LEIs) of the ligands [31,32], facilitates a comparison of the chemical–
biological space of binders at different regions, thus guiding the selection of the most
druggable sites for compound development.
The aim of this study was two-fold; first, to identify novel and druggable ligand
binding sites in KIM-PTPs that define a more favourable chemical–biological space than
the highly polar active site. Second, to explore if those druggable sites may offer selective
inhibition across different families of PTPs. For this we have used VSpipe, a virtual
screening pipeline, on the three KIM-PTPs and defined a ligand cluster distribution that
is unique to this subfamily of PTPs, with several clusters located on KIM-PTP sequence
specific motifs [33]. This is in contrast to the cluster distribution obtained for PTP1B [29]
that mapped mainly to the conserved classic PTP motifs [34].
Assessment of the unique KIM-PTP binding clusters using LEI plots ascertained that
the binders at the KIM-PTP specific clusters reside in a more drug like chemical–biological
space than that of binders at the active site. Further to this, LEI analysis demonstrated
that the chemical–biological space in which binders of KIM-PTP specific clusters reside
is unique to each phosphatase. Structural analysis defined key features responsible for
the differences at the cluster binding sites. These features may be used in the design and
development of inhibitors that are selective amongst the KIM-PTPs and that have more
drug-like properties.
2. Results and Discussion
2.1. VSpipe Blind Docking Comparison of the KIM-PTPs
Targeting of the open, super-open and allosteric sites has been suggested as an ap-
proach to yield compounds of improved physiochemical properties when compared to
those of active site inhibitors [23]. Thus, the receptor models for the three KIM-PTPs used in
this study were all in the open conformation and obtained from crystallographic structures
deposited in the protein data bank for PTP-SL (PDB ID: 1JLN), STEP (PDB ID: 2BV5) and
HePTP (PDB ID: 3O4U). However, in the open structure of HePTP, due to the flexibility of
certain regions, there are missing residues in the deposited structures [35]. Therefore, we
used Modeller [36] to generate a complete model (see methods for details). For the open
form structure 3O4U, residue sequences 257DHQTP261 (downstream of the WPD-loop) and
196QLREGKEKC204 (E-loop) were modelled (Supplementary Figure S1). The 257DHQTP261
loop is very flexible, thus caution is advisable when considering the exact conformation of
this region. However, confidence in the model generated can be drawn from similarities to
previous examples in the literature; for example, the structure of the super-open form of
RPTPγ that was exploited to obtain nanomolar range inhibitors [24].
To aid identification of new ligand binding sites on the KIM-PTPs, we carried out
blind docking with VSpipe [29] against each KIM-PTP, using the Asinex fragment library
(composed of 6243 chemical fragments).
Blind docking identified several ligand clusters (a cluster being greater than ten
fragments at a specific site) at different binding sites (Figure 1). To aid our understanding
of the functional relevance of these clusters, we mapped onto the structures the previously
identified unique sub-family sequence motifs specific for KIM-PTPs (K2-K8), not shared
by other PTPs [33] (Figure 1). Specifically, the location of the five clusters identified for
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HePTP were as follows: C1, active site; C2, open pocket; C3, a site of importance for p-ERK
peptide binding [37]; C4, K3, K5 and K7 motifs; C5, K5 to K7 motifs. The C2 binding site is
created by the open conformation of WPD loop that reveals a pocket above the active site.
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Figure 1. Blind docking results for kinase interaction motif protein tyrosine phosphatases KIM-PTPs (HePTP, PTPSL and
STEP). The structure of the three KIM-PTPs are shown as a grey surface with key functional KIM-PTP specific motifs [33]
coloured as follows: K2 in yellow, K3 in orange, K4 in red, K5 in magenta, K6 in cyan, K7 in blue, K8 in green. Compounds
are shown as lines. Areas where there is a high density of compounds (greater than 10) are classified as clusters and
numbered: C1, active site; C2, open form pocket; C3, substrate-binding site; C4, centred between K3, K5 and K7; and C5,
centred on K5, K6 and K7; C6, centred on K8; C7 above open pocket; and C8 below the active site. The front view and back
view for a l thr e KI -PTPs are sho n. For STEP, si e ie is ls s t l t .
For PTP-SL, blind docking identified five clusters of fragments (Figure 1). Four of
them are located at the sites identified for HePTP: C1, active site; C2, open pocket; C4,
K3, K5 and K7 motifs; and C5, K5 to K7 motifs. A further cluster, C6, that resides at the
K8 motif, was also observed. Interestingly, C3 was not identified for PTP-SL, suggesting
potential for selectivity. For STEP, seven clusters of fragments were identified (Figure 1),
many located at sites that were common to HePTP and PTP-SL: C1, active site; C2, open
pocket; C5, K5 to K7 motifs; and C6, K8 motif; whilst the C4 site found for HePTP and
PTP-SL represented a low density binding site (defined as less than 10 fragments) in STEP.
However, there were additional clusters in STEP: C7, in-between the open pocket and K8;
C8, below the active site; and C9, a cluster that resides between K6 and K8 motifs. Clusters
C7 and C8 were not identified on the other two KIM-PTPs, thus these sites may afford
opportunities for selective interaction, although functional importance of these sites is
unclear. C9 is more interesting as it only appears in STEP and also locates to the KIM-PTP
specific motifs K6 and K8.
In summary, blind docking identified several ligand clusters, some of which reside at
sites that are unique to the KIM-PTPs, exploring binding capabilities beyond the conserved
active site. Differences are also apparent between the three KIM-PTPs, suggesting these
different binding sites may offer opportunities to exploit selectivity.
2.2. Ligand Efficiency Analysis of Binders at Clusters 1, 4, 5 and 6
Clusters 4, 5 and 6 are located on KIM-PTP specific motifs and sites associated
with clusters 4 and 5 were identified as potential druggable pockets (score > 0.5) by
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DoGSiteScorer (DGSS) [38] (Table 1). DGSS measures the volume of any pocket of interest
and the amino acid composition, and calculates a druggability score, which indicates
whether it is likely drug-like compounds will interact with the pocket. For STEP, DGSS
identified two small pockets associated with C6 which we refer to as C6 and C6′, although
the score is low. For HePTP, DGSS identified a large pocket including C1 and C2 (Table 1)
with high druggability score. Thus, we decided to further explore these KIM-PTP specific
clusters (C4–C6) by conducting targeted docking with VSpipe-Vina [29] at the associated
pockets and at the active site (C1) for comparison.
Table 1. Druggability scores calculated by DoGSiteScorer [38] of the pockets associated with clusters 1, 4, 5 and 6 for HePTP,
PTPSL and STEP.
PTP Pocket (Site of Cluster) Druggability Probability Vol. Hull/Å3 % Polar Residues
HePTP C1/C2 0.83 617 39
HePTP C4 0.61 324 39
HePTP C5 0.81 522 29
HePTP C6 0.27 135 10
PTP-SL C1 0.61 428 45
PTP-SL C4 0.55 259 50
PTP-SL C5 0.74 604 29
PTP-SL C6 0.37 177 20
STEP C1 0.51 280 53
STEP C4 0.24 187 67
STEP C5 0.72 475 37
STEP C6 0.34 155 50
STEP C6′ 0.23 134 50
Targeted docking at C1, C4, C5 and C6 was done with VSPipe using the Chembridge
Diverset library (50,000 compounds) for all three KIM-PTPs with the same models as for
the blind docking. The results of the docking were sorted by binding affinity (∆G) and
filtered to select the top 500 binders for further analysis.
The highest average binding score for HePTP and STEP was found in the C5 cluster
with an average ∆G of −8.2 and −8.5 kcal/mol, respectively. In contrast, the highest aver-
age score in PTP-SL was for the C1 cluster with ∆G of −8.7 kcal/mol (Table 2). Although
the ∆G values may offer an estimate of the binding affinity, they provide little information
on the drug-like nature of the ligands. This can be assessed using the ligand efficiency
index (LEI) plots generated by VSpipe [29] (Figure 2). These plots correlate the binding
efficiency of the ligands with two important physiochemical properties that impact on the
pharmacokinetic and oral bioavailability of the compounds: molecular weight and polar
surface area. Optimisation of these properties, together with potency, aid the development
of drug-like compounds [31]. The SEI and BEI efficiency indices are of particular interest
where SEI is the surface-binding efficiency index in respect to polar surface area, and BEI is
the binding efficiency index related to the molecular weight. The equations for these LEIs
are provided in the methods.
The application of these plots to PTP drug discovery has been demonstrated in
the literature [32,39], and shown to unveil unique opportunities to explore alternative
functional sites to the highly conserved active site [29,30]. The NSEI/nBEI plots generated
by VSpipe for each targeted docking were used to assess how the LEI profiles of clusters
1, 4, 5 and 6 vary across the KIM-PTPs (Figure 2). In these plots the ligands are sorted
according to the number of polar atoms (nitrogen, oxygen) or NPOL planes, along which
efficiency increases from the bottom to the top of each [39] (Figure 2).
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Table 2. Binding affinities (∆G) of the top 500 binders from targeted docking of the Chembridge Diverset library at the
pockets associated with clusters 1, 4, 5 and 6 for HePTP, PTPSL and STEP.
PTP Cluster ∆G Low (kcal/mol) ∆G High (kcal/mol) ∆G Average (kcal/mol)
HePTP 1 −6.7 −8.3 −6.9
HePTP 4 −7.7 −9.0 −7.9
HePTP 5 −8.0 −9.4 −8.2
HePTP 6 −7.7 −9.1 −7.9
PTP-SL 1 −8.5 −9.8 −8.7
PTP-SL 4 −7.3 −8.2 −7.5
PTP-SL 5 −8.0 −9.3 −8.2
PTP-SL 6 −7.4 −8.7 −7.6
STEP 1 −7.2 −9.1 −7.4
STEP 4 −7.0 −8.0 −7.2
STEP 5 −8.3 −10.1 −8.5
STEP 6 −6.6 −7.5 −6.8
For C1, the distribution of binders was similar for all three KIM-PTPs, with the larger
number of ligands along the NPOL 5 to 7. The best scorer was located on NPOL 7 for all
three KIM-PTPs, demonstrating a high dependency of efficient binders at this site (active
site) on polarity. The most efficient ligands at any NPOL line were binders of PTP-SL,
whilst the least efficient on all NPOL lines were binders of HePTP (Figure 2A). This is in
good agreement with the ∆G average values from the VSpipe docking (Table 2).
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The analysis of the chemical–biological space distribution for the cluster ligands 
highlighted differences between the three KIM-PTPs. To understand these differences and 
the determinants for ligand affinity and polarity, we analysed the structural properties of 
the corresponding binding sites. 
C1 ligands, binding at the active site, showed a clear preference for PTP-SL with a 
ΔG average of −8.7 with respect to HePTP (−6.9) or STEP (−7.4) (Table 1). The PTP-SL ac-
tive site also has a higher druggablity score than the active site of the other KIM-PTPs 
(Table 2). The main reason for these differences is, in part, the volume of the pocket that 
for PTP-SL is 428 Å3, whereas for STEP is only 280 Å3. The percentage of polar residues at 
this site was also lower for PTP-SL (45%) than for STEP (53%), and consequently cluster 
binders reside in a more drug-like space. For HePTP, the pocket is larger because it merges 
with the open pocket, making comparisons difficult. 
The binders of the highest affinity in C4 were those that targeted HePTP, whilst STEP 
C4 binders had the lowest affinity and resided in the least drug-like chemical–biological 
space. The associated pocket of C4 in HePTP also had the highest drugability score (Table 
2). The main differences in the C4 pocket across the KIM-PTPs are its size and the access 
to this pocket. In HePTP, the C4 pocket is the largest with 324 Å3. However, in STEP, access 
to the pocket is partially blocked by the side chain of K502, resulting in a considerably 
smaller pocket at 187 Å3. In HePTP, this residue is a glycine, G257, and in PTP-SL a serine, 
S510 (Figure 3), both having smaller size side chains than K502. The C4 pocket for STEP 
is also more polar (composed of 67% polar residues) than that of the pocket for HePTP 
(39% polar residues) and PTP-SL (50% polar residues). This is, in part, a consequence of 
the replacement of an isoleucine in PTP-SL and HePTP with a threonine in STEP. This size 
difference and access to the pocket would be less favourable during docking, thus explain-







































































































Figure 2. VSpipe NSEI/nBEI plot analysis of selected ligands (top 500 ranked by ∆G) for clusters 1, 4, 5 and 6 for the
KIM-PTPs (HePTP, PTPSL and STEP). Each panel is an NSEI/nBEI plot of the cluster ligands for the three KIM-PTPs:
(A) cluster 1 binders, (B) cluster 4 binders, (C) cluster 5 binders, and (D) cluster 6 binders. The dots represent individual
ligands and the colouring is as follows: HePTP (blue), PTP-SL (red), and STEP (green). Each diagonal line of compounds
represents a specific NPOL (number of N and O atoms i the compound) as given by the number above each diagonal line.
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Analysis of the C4 binders (Figure 2B) also showed a similar distribution of binders
across NPOL lines for all three KIM-PTPs, with the highest populations on the NPOL 5 and
6 lines. Differences were observed for the best scorer, located on NPOL 6 for HePTP and
STEP, and NPOL 8 for PTP-SL, indicating that PTP-SL binders show higher polarity. The
most efficient binders across all NPOL planes are HePTP ligands, whilst the C4 binders of
STEP are the least efficient.
C5 binders (Figure 2C) show the highest distribution on the NPOL 4 to 6 lines, with
the best scorers located on NPOL 5 for HePTP and PTP-SL, and on NPOL 4 for STEP.
Thus, the site associated with C5 favours more hydrophobic binders than the other clusters,
particularly for STEP. The most efficient ligands on each NPOL line were binders of STEP,
and the least efficient binders were for PTP-SL. STEP C5 binders reside in the best chemical
biological space (top-right quadrant) in contrast with its binders at the other clusters
(bottom-left), thus this site represents a good opportunity to exploit selectivity for this
phosphatase over the others in the same subfamily.
For C6 (Figure 2D), the distribution of binders was also similar for all three KIM-PTPs,
with the highest distribution on the NPOL 5 to 7 lines, and the best scorers located on
NPOL 6. This suggests there is little difference in the preference of polarity across the
KIM-PTPs at the site associated with cluster 6. The most efficient ligands on each NPOL
line were binders of HePTP and PTP-SL binders, whilst the least efficient were binders
of STEP.
In summary, the LEI analysis, together with the druggability scores, support the notion
that there are sufficient differences between the three KIM-PTPs that could be exploited
to develop selectivity using different binding sites. For example, C1 for PTP-SL, C4 for
HePTP or C5 for STEP, as discussed above.
2.3. Structural Analysis of the Cluster Binding Sites
The analysis of the chemical–biological space distribution for the cluster ligands
highlighted differences between the three KIM-PTPs. To understand these differences and
the determinants for ligand affinity and polarity, we analysed the structural properties of
the corresponding binding sites.
C1 ligands, binding at the active site, showed a clear preference for PTP-SL with a ∆G
average of −8.7 with respect to HePTP (−6.9) or STEP (−7.4) (Table 1). The PTP-SL active
site also has a higher druggablity score than the active site of the other KIM-PTPs (Table 2).
The main reason for these differences is, in part, the volume of the pocket that for PTP-SL
is 428 Å3, whereas for STEP is only 280 Å3. The percentage of polar residues at this site
was also lower for PTP-SL (45%) than for STEP (53%), and consequently cluster binders
reside in a more drug-like space. For HePTP, the pocket is larger because it merges with
the open pocket, making comparisons difficult.
The binders of the highest affinity in C4 were those that targeted HePTP, whilst STEP
C4 binders had the lowest affinity and resided in the least drug-like chemical–biological
space. The associated pocket of C4 in HePTP also had the highest drugability score (Table 2).
The main differences in the C4 pocket across the KIM-PTPs are its size and the access to
this pocket. In HePTP, the C4 pocket is the largest with 324 Å3. However, in STEP, access
to the pocket is partially blocked by the side chain of K502, resulting in a considerably
smaller pocket at 187 Å3. In HePTP, this residue is a glycine, G257, and in PTP-SL a serine,
S510 (Figure 3), both having smaller size side chains than K502. The C4 pocket for STEP
is also more polar (composed of 67% polar residues) than that of the pocket for HePTP
(39% polar residues) and PTP-SL (50% polar residues). This is, in part, a consequence of
the replacement of an isoleucine in PTP-SL and HePTP with a threonine in STEP. This
size difference and access to the pocket would be less favourable during docking, thus
explaining why a low-density cluster is observed for STEP.
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The C5 cluster (Figure 4), binding across K5, K6 and K7, was the only example where
binders showed higher affinity for STEP and ligands resided in the most drug-like space.
Inspection of the C5 binding pocket for the three KIM-PTPs shows a deeper pocket for
STEP that may afford higher binding affinity. A key residue at the bottom of the pocket
is the phenylalanine residue of the K7 motif (Figure 4), a conserved residue across the
KIM-PTPs that adopts the same conformation in all three proteins. The reason why PTP-SL
ligands appear to have lower affinity is the presence of R467 that blocks access to F490 and
results in a smaller opening of the pocket (Figure 4). This residue is an alanine in STEP, and
in HePTP this region is a disordered loop instead of helical, thus leaving it more open to
access the pocket (Figure 4). However, in HePTP, R241 at the top of the pocket partially
obstructs access to F237. This residue is a serine in both PTP-SL and STEP (Figure 4).
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Another important difference between the three KIM-PTPs is the loop that forms a lip
at the bottom entrance of the pocket (coloured yellow, red and orange for STEP, PTP-SL and
HePTP, respectively, in Figure 4). The sequence of this eight-residue loop (ten residues in
HePTP) is not conserved, and this is reflected on its conformation in the crystal structures.
In HePTP, it adopts a wide-open conformation, leaving a larger pocket. In STEP, it adopts
a more closed position, creating a deep pocket, and in PTP-SL it adopts an intermediate
position. The binding site associated with C5 is the only cluster that may deliver selectivity
for STEP over the other two KIM-PTPs, given the considerable differences in pocket
architecture and sequence. This pocket also shows the highest druggability scores for all
KIM-PTPs and the lowest percentage of polar residues.
Finally, the highest affinity binders in C6 were those that targeted HePTP, whilst
STEP binders had the lowest affinity and resided in the least drug-like chemical–biological
space. The differences in surface topography at the C6 binding site can be explained when
considering the conformation of the WPD-loop and its position in respect to the helix that
precedes the K3 motif (Figure 5A). In the case of HePTP and PTP-SL, the WPD-loop is far
away from the helix (>9 Å), thus generating space for a larger pocket (Figure 5B,D). For
STEP, the loop is considerably closer to the helix (<7 Å), thus splitting the pocket into two
smaller pockets C6 and C6′ (Figure 5C).
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Figure 5. Structural analysis of the pocket associated with cluster 6 across the three KIM-PTPs
(HePTP, PTPSL and STEP). (A) Different conformations of the WPD loop across the KIM-PTPs are
shown in cartoon format. (B–D) The effect of the position of WPD-loop on the size and shape of the
pocket associated with cluster 6 is shown, with the three KIM-PTPs being represented as surfaces.
The colouring is as follows: the K8 motif is green, whilst the WPD loop is coloured orange (HePTP),
yellow (STEP), and red (PTP-SL).
Furthermore, the C6 and C6′ sites in STEP contained a much higher percentage of polar
residues, thus ligands there reside in the least favoured chemical–biological space (bottom-
left quadrant of the NSEI/nBEI plot) (Figure 2D). Exploiting this pocket for inhibitor
development may afford selectivity to HePTP and PTP-SL over STEP. Further to this,
selectivity may be possible between HePTP and PTP-SL given the differences in size and
shape of the C6-site between both proteins. However, all pockets associated with C6 have
poor druggability scores relative to the pockets associated with C4 and C5 (Table 2).
2.4. Blind Docking Clusters Are Subfamily Specific
Most of the clusters identified for the KIM-PTPs are centred on motifs that are specific
to this subfamily of PTPs [33]. To test the use of blind docking as a PTP profiling approach
Int. J. Mol. Sci. 2021, 22, 12206 9 of 14
based on cluster distribution, we carried out blind docking against PTP1B in its open form
(PDB ID: 1T4J) with the Asinex fragment library. This resulted in the identification of six
clusters of fragments (Figure 6), together with four low-density binding sites (less than
ten fragments at each site). The clusters located at the following motifs or regions: C1, the
active site [34]; C2, the secondary phospho-tyrosine binding site [40]; C3, a site centred on
L41; C4, an allosteric binding site [25]; C5, a site centred on V155; and C6, a site centred
on E252.
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Figure 6. Blind docking cluster comparison between HePTP and PTP1B. The structure of HePTP
(top) is shown as a grey carto n, key functional KIM specific motifs [33] have been col ured on the
HePTP structure, K2 in yellow, K3 in orange, K4 in red, K5 in magenta, K6 in cyan, K7 in blue, K8 in
green. Compounds are shown as lines. Ligand clusters with more than ten compounds are numbered:
C1, active site; C2, open form pocket; C3, substrate-binding site; C4, centred on K3, K5 and K7 motifs;
C5, centred on K5–K7 motifs. The structure of PTP1B is shown as a grey cartoon (bottom), front view
and back view. Clusters are numbered: C1, active site; C2, secondary pTyr site; C3, centred on L41;
C4, allosteric binding site; C5, centred on V155; and C6, centred on E252. Key PTP motifs [33] have
been coloured on the structure: PTP1 in red; PTP 2, magenta; PTP 3, cyan; PTP 4, blue; PTP 5, green;
and PTP6, yellow.
The only common cluster between KIM-PTPs, exemplified by HePTP and PTP1B,
is the cluster at the active site (C1), with all other HePTP clusters locating at KIM-PTP
specific motifs. Thus, binders at these sites may deliver KIM-PTP specific inhibitors over
the classical PTP1B.
2.5. Functional Correlation with Cluster Distribution
In an effort to validate the functional importance of the cluster distribution, we
mapped the position of the identified clusters to that of reported substrates, inhibitors
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and activators of KIM-PTPs. In the case of STEP, the C1 cluster overlaps with the core
structure of a STEP active site inhibitor (5OW1 [18]), and it extends towards a sub-pocket
nearby suggesting a possible target for expansion in future development of active site
inhibitors (Figure 7A). Blind docking also identified the site of the recently developed
allosteric activators of STEP (6H8S, 6H8R, [19]). The C5 cluster overlaps with these allosteric
activators, and highlights potential regions for additional interactions at a secondary pocket
where ligands bind (Figure 7B).
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Figure 7. Functional correlation with cluster distribution. (A) Surface representation of STEP with
C1 cluster (grey lines) overlaid onto a STEP active site inhibitor (green sticks) [18]. (B) STEP C5
cluster (grey lines) overlaid onto a STEP allosteri activator (magenta sticks) [19]. The STEP surface
is coloured as f llows: K5 in magenta, K6 in cyan, and K7 in blue. (C) Structure of He TP with C3
cluster (grey lines) shown together with the HePTP substrate p-ERK (cyan sticks) [37]. (D) Structure
of PTP1B as a gold surface in complex with the bi-dentate inhibitor IX1 (green sticks) [41]. Key
residues in the secondary p-Tyr binding site are labelled.
The binding site associated with C3 in HePTP (Figure 7C) is particularly interesting
since a cluster at this site was not observed for either of the other two KIM-PTPs or PTP1B,
suggesting it may be a key driver of selectivity. The C3 cluster partially overlaps with the
position of the p-ERK peptide substrates binding in this region (3D42 [37]), and many of
the ligands form interactions with H237 and the mutated D106, both critical residues in
regulating substrate binding. This may open up avenues for the development of bi-dentate
or pseudo-peptide inhibitors that mimic the biological substrates of HePTP. Bi-dentate
inhibitors that target the C3 binding region may afford selectivity over PTP1B, where the
position of Y20, R24 and Q262 in the pTyr secondary site nearby would clash with the C3
ligands. Conversely, double-site inhibitors of PTP1B (1XBO [41]) exploit the pTyr secondary
site (Figure 7D), which in HePTP is blocked by F87, a conserved residue in all KIM-PTPs.
3. Materials and Methods
3.1. Preparation of the Models
The catalytic domain sequence of HePTP was downloaded from www.uniprot.org,
accessed on 2 November 2020. The 3D structure used as template for the open form of
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HePTP was obtained from the Protein Data Bank (https://www.rcsb.org, accessed on
2 November 2020). For the modelling, the basic option in Modeller was utilised, with PDB
ID: 3O4U. The residue sequences 257DHQTP261 and 196QLREGKEKC204 were modelled.
Residues 256P and 262E flanking 257DHQTP261 were kept rigid. Five complete models
for both regions were generated and the model for each loop with the lowest modeller
objective function score was selected for subsequent docking.
The structures of PTP-SL (PDB ID: 1JLN), STEP (PDB ID: 2BV5) and PTP1B (PDB ID:
1T4J) were used as starting models for docking without further modifications.
3.2. Virtual Screening with VSpipe
VSpipe v1.0 [29] was used for all the blind and targeted docking, as well as the
generation of the ligand efficiency (LEI) plots. VSpipe [29] is a semi-automated pipeline
that uses MGLTools, AutoDock tools [42], OpenBabel [43], and in-house Python and R
scripts to perform structure-based virtual screening.
Blind docking was performed with the VSpipe-Vina [29] option for all targets using
a grid spacing of 0.375 Å, and a box size sufficient to include the whole protein structure.
Blind docking was carried out with the Asinex BB v123 SD library (www.asinex.com,
accessed on 15 April 2018) that contains 6243 chemical fragments. The compounds are
low molecular weight building blocks and abide by the following rules molecular weight
120–250, cLogP < 2.5, HBA < 7, HBD < 4.
For the analysis of HePTP, we used the following grid centre: x = 12.254, y = 17.806,
z = −22.012. For PTP-SL, we used: x = 18.520, y = −5.430, z = 8.985. For STEP, we used:
x = 11.136, y = −10.835, z = −16.125. For the analysis of PTP1B, we used the following grid
centre: x = 56.500, y = 31.333, z = 22.113.
Targeted docking was performed with VSpipe-Autodock [29] using the default stan-
dard protocol for non-covalent ligands. The box size for all proteins and sites explored was
15 × 15 × 15 Å3, and a spacing of 0.375 Å was used. Docking was done with the Chem-
bridge Diverset library composed of 50,000 compounds. This library contains a diverse
collection of lead-like molecules (www.cambridgemedchemconsulting.com/DDResources/
Hit_iden/frag_collection.html, accessed on 15 April 2018).
The parameters used for each protein are as follows. For HePTP targeted docking, the
grid centre used for the cluster 1 was: x = −7.367, y = 20.032, z = −17.759; for cluster 3, it
was: x = −28.392, y = 21.340, z = −17.759; cluster 5 was: x = −5.493, y = 0.912, z = −12.290;
for cluster 6, it was: x = −27.866, y = 1.499, z = −6.069; for cluster 7, it was: x = −32.148,
y = 5.340, z = −23.870. For PTPSL, the grid centre used for the cluster 1 was: x = 14.125,
y = −8.987, z = 6.586; for cluster 3, it was: x = 35.369, y = −16.222, z = 3.589; for cluster 6, it
was: x = 40.107, y =−10.355, z = 24.945; for cluster 7, it was: x = 31.332, y = 8.029, z = 18.912.
For STEP, the grid centre used for the cluster 1 was: x = 7.321, y = −18.826, z = −17.129;
for cluster 3, it was: x = 19.086, y = −18.085, z = −38.811; for cluster 6, it was: x = 31.193,
y = −5.244, z = −21.540; for cluster 7, it was: x = 25.555, y = 6.644, z = −15.12.
All computational tasks were carried out at the Computational Shared Facility (CSF)
at the University of Manchester.
3.3. Ligand Efficiency (LEI) Plots
All LEI plots used to analyse the binding clusters in this study were generated from
VSpipe using the following equations taken from [32]:
NSEI (−log10Ki/NPOL) vs. nBEI (−log10[(Ki/NHEA)]), and SEI (p(Ki)/(PSA/100
Å2) vs. BEI (p(Ki)/MW(kDa)). The plots help to visualise the chemical–biological space for
each ligand cluster obtained from the targeted docking.
3.4. Pocket Druggability Predictions
Pocket druggability predictions were performed using the DoGSiteScorer server
https://proteins.plus/#dogsite, accessed on 27 May 2020. The software makes predictions
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regarding protein pockets using a variety of physiochemical and geometric discriminators
to yield a mean druggability score; the greater the score, the more druggable the pocket [38].
Structural analyses and figures were prepared with MacPyMOL: PyMOL v1.8.0.3
Enhanced for Mac OS X (Schrödinger LLC, New York, NY, USA).
4. Conclusions
In this work we present the use of blind docking with the virtual screening tool VSpipe,
to identify allosteric ligand binding sites that are specific to the subfamily of KIM-PTPs.
The VSpipe blind docking on KIM-PTPs (HePTP, STEP, PTP-SL) resulted in a unique cluster
distribution, different to that observed previously for the classic PTP1B [29]. Therefore, the
VSpipe blind docking approach may offer a way of profiling PTPs at the subfamily level.
Differences in the binding site druggability and the profile of the ligand clusters
between each KIM-PTP highlighted the potential for selective inhibition, even within the
subfamily. Importantly, several of the clusters identified reside at sites of known functional
relevance for activity or substrate binding specific to the KIM-PTPs. An assessment of the
drug-like properties of ligands at each binding site was facilitated by analysis of LEI plots
generated by VSpipe targeted docking at the cluster sites. From this, it was ascertained that
several of the KIM-PTP specific binding sites selected ligands residing in a more drug-like
chemical space than those binding to the active site, which is highly polar. Differences were
observed when comparing the ligand clusters from different KIM-PTPs, either in respect to
their position or their LEI profile.
Structural analysis of the most druggable sites allowed a rationalisation of the dif-
ferences in binding and in the LEI profiles across the KIM-PTP subfamily of enzymes,
providing a rationale for further inhibitor development to achieve selectivity.
VSpipe provides a quick, easy and cost-effective stepwise approach for the identifica-
tion of new sites to target for drug development, particularly allosteric sites. The combined
analysis of the targeted docking with that of the LEI profiles of ligand clusters facilitates the
identification of specific binding sites that may afford selective inhibition and development
of drug-like binders. Ultimately, this work opens up a new paradigm for the development
of KIM-PTP inhibitors, as well as phosphatase inhibitors, and more widely to any drug
target of interest.
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